Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30474060 | 1.00 | FAAH (0.57) | FAAHHDAC1HDAC6IMPDH2ALDH1A1 | |
| SCHEMBL25213509 | 0.85 | ALDH1A1 (0.50) | FAAHHDAC1HDAC6IMPDH2ALDH1A1 | |
| SCHEMBL25247852 | 0.82 | FAAH (0.63) | FAAHHDAC1HDAC6IMPDH2ALDH1A1 | |
| SCHEMBL26388277 | 0.80 | HPGD (0.44) | FAAHIMPDH2TSHRHPGDHSD17B10 | |
| SCHEMBL6932257 | 0.80 | PDE7A (0.44) | ALDH1A1HPGDHSD17B10KDM4ETDP1 | |
| SCHEMBL25242500 | 0.80 | ALDH1A1 (0.43) | FAAHALDH1A1TSHRHSD17B10KDM4E | |
| SCHEMBL30474070 | 0.80 | ALDH1A1 (0.43) | FAAHALDH1A1TSHRHSD17B10KDM4E | |
| SCHEMBL892373 | 0.80 | FAAH (0.52) | FAAHHDAC1HDAC6ALDH1A1HPGD | |
| SCHEMBL30301346 | 0.79 | FAAH (0.57) | FAAHHDAC1HDAC6IMPDH2ALDH1A1 | |
| SCHEMBL6919654 | 0.76 | TARBP2 (0.54) | FAAHHDAC1HDAC6MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2025-01-30 | — | — | US | disclosed |
| EP-4441044-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| CN-118302422-A | Substituted N-cyanopyrrolidines having activity as USP30 inhibitors | 特殊治疗有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023099561-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023099561-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034122-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP47, USP1 | FAAH 1830/4885HDAC1 560/4885HDAC6 764/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | FAAH 737/4885HDAC1 1902/4885HDAC6 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.